Lomefloxacin

Ophthalmic
Bacterial conjunctivitis

Oral
Acute bacterial exacerbation of chronic bronchitis

Oral
Prophylaxis of surgical infections

Oral
Complicated urinary tract infections

Oral
Uncomplicated urinary tract infections

Otic/Aural
Otitis externa, Otitis media

Oral:
Uncomplicated and complicated urinary tract infections; Acute bacterial exacerbation of chronic bronchitis:
Haemodialysis; CrCl 10-40 mL/min/1.73 m²: Initially, 400 mg as a single dose, followed by maintenance doses of 200 mg daily.

May be taken with or without food.

Hypersensitivity to the drug or other quinolones; children <18 yr; pregnancy and lactation.

Avoid prolonged exposure to sunlight or artificial UV light. Known or suspected CNS disorders e.g. severe cerebral arteriosclerosis, epilepsy or other factors that predispose to seizures. Avoid in patients with known QT prolongation, uncorrected hypokalaemia. May impair ability to drive or operate machinery. Renal impairment.

Nausea, abdominal pain or discomfort, diarrhoea; headache, dizziness, insomnia; rash, pruritus, photosensitivity; thrombocytopenia.
Potentially Fatal: Anaphylactic or anaphylactoid reactions.

PO: C

Empty the stomach by inducing vomiting or by gastric lavage. Treatment is supportive. Maintain adequate hydration. Haemodialysis or peritoneal dialysis is unlikely to be helpful.

Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.
Potentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.

Description:
Mechanism of Action: Lomefloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
Pharmacokinetics:
Absorption: Rapid and complete from the GI tract (oral); peak plasma concentrations after 1-1.5 hr. Absorption delayed with food.
Distribution: Widely distributed; lungs and prostate. Protein-binding: 10%.
Excretion: Via urine (as unchanged drug and small amounts of glucuronide metabolites); may be prolonged in renal impairment. Via faeces (small amounts as unchanged drug); 7-8 hr (elimination half-life).

Oral:
Uncomplicated urinary tract infections: Store at 15-25°C (59-77°F).
Prophylaxis of surgical infections: Store at 15-25°C (59-77°F).
Acute bacterial exacerbation of chronic bronchitis: Store at 15-25°C (59-77°F).

Ear Anti-Infectives & Antiseptics / Eye Anti-Infectives & Antiseptics / Quinolones